What is the 13F Pro Quality Score for STRO?

13F Pro ranks SUTRO BIOPHARMA, INC. (STRO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STRO's current score at https://13fpro.ai/research/STRO (free sign-up required for the full ranking).

Which hedge funds own the most STRO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STRO include BVF /IL, Affinity Asset Advisors,, Samsara BioCapital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/STRO as soon as new 13F filings post.

Where does 13F Pro source STRO data?

All SUTRO BIOPHARMA, INC. fundamentals and ownership data come directly from SEC EDGAR. SUTRO BIOPHARMA, INC. files with the SEC under CIK 1382101. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STRO in?

SUTRO BIOPHARMA, INC. (STRO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STRO research updated on 13F Pro?

STRO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SUTRO BIOPHARMA, INC.(STRO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1382101 STRO stock profile & AI dashboard →

13F Pro Quality Score

30.1/100

Rank #2,372 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.8/100

Profitability

5.8/100

Balance Sheet

0.6/100

Earnings Quality

30.0/100

Free Cash Flow

5.2/100

Institutional Flow

99.9/100

Revenue Scale

18.1/100

Dilution Risk

13.4/100

STRO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SUTRO BIOPHARMA, INC. (STRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STRO at 30.1/100 on a 32-signal composite quality model, placing it at rank #2,372 of 2,879 stocks — the bottom half of the AI-ranked universe. STRO scores in the top quartile across institutional flow (99.9), revenue growth (90.8). Areas of concern include balance sheet strength (0.6) and free cash flow (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SUTRO BIOPHARMA, INC. reports quarterly revenue of $14.5M, net income of $-38.5M, free cash flow of $-42.3M. Top institutional holders of STRO by reported 13-F value include BVF /IL, Affinity Asset Advisors,, Samsara BioCapital,, based on the most recent SEC filings. STRO trades on the Nasdaq exchange and files with the SEC under CIK 1382101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUTRO BIOPHARMA, INC. directly from SEC EDGAR. SUTRO BIOPHARMA, INC.'s 13F Pro composite quality score has ranged between 11 and 30 since 2021, currently 30.1 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q1 2026

$14.5M

Net Income

Q1 2026

$-38.5M

Free Cash Flow

Q1 2026

$-42.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+65.2% YoY

$102.5MFY 2025

FY21 $61.9MFY23 $153.7MFY24 $62.0MFY25 $102.5M

Net Income

+15.9% YoY

$-191.0MFY 2025

FY21 $-105.5MFY23 $-106.8MFY24 $-227.0MFY25 $-191.0M

Operating Income

+33.6% YoY

$-158.4MFY 2025

FY21 $-98.5MFY23 $-89.3MFY24 $-238.5MFY25 $-158.4M

EPS (Diluted)

+23.5% YoY

$-22.49FY 2025

FY21 $-2.29FY23 $-1.78FY24 $-29.40FY25 $-22.49

Total Assets

-55.1% YoY

$173.8MFY 2025

FY21 $341.4MFY23 $470.7MFY24 $387.2MFY25 $173.8M

Total Debt

—FY 2025

FY21 $43.9MFY23 $12.2MFY24 —FY25 —

Op. Cash Flow

+7.5% YoY

$-177.2MFY 2025

FY21 $-81.7MFY23 $-111.6MFY24 $-191.5MFY25 $-177.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$102.5M +65.2%	$62.0M -59.6%	$153.7M +148.4%	$61.9M +44.8%	$42.7M -0.0%	$42.7M
Net Income	$-191.0M +15.9%	$-227.0M -112.6%	$-106.8M -1.2%	$-105.5M -228.5%	$-32.1M +73.0%	$-119.2M
Operating Income	$-158.4M +33.6%	$-238.5M -167.1%	$-89.3M +9.4%	$-98.5M -38.7%	$-71.1M -28.1%	$-55.5M
EPS (Diluted)	$-22.49 +23.5%	$-29.40 -1551.7%	$-1.78 +22.3%	$-2.29 -131.3%	$-0.99	—
Total Assets	$173.8M -55.1%	$387.2M -17.7%	$470.7M +37.9%	$341.4M -13.4%	$394.1M +152.0%	$156.4M
Total Debt	—	—	$12.2M -72.2%	$43.9M +78.7%	$24.5M +148.5%	$9.9M
Operating Cash Flow	$-177.2M +7.5%	$-191.5M -71.6%	$-111.6M -36.7%	$-81.7M -20.5%	$-67.8M -4.3%	$-65.0M

AI Insight: STRO Financial Trends

Sutro is burning cash and equity while revenue remains volatile—company has turned insolvent and lacks a clear path to profitability.

• Revenue highly volatile: $26M (Q2 2024) to $9M (Q3 2024), peaked at $64M (Q2 2025), then collapsed to $10–15M range (Q3 2025–Q1 2026).

• Operating losses narrowed from $49–$69M per quarter (Q2–Q4 2024) to $30–$48M (Q3 2025–Q1 2026), but only modestly.

• Equity swung sharply negative: $152M (Q2 2024) to $-132M (Q4 2025), indicating liabilities now exceed assets by material amount.

⚠ Operating cash flow deeply negative in most quarters; only Q2 2024 posted $9M positive CF amid massive operating losses.

⚠ Q2 2025 anomaly: $64M revenue spike did not improve profitability or cash generation; sustainability unclear.

⚠ Insolvency since Q1 2025; company has no visible debt on balance sheet but shareholders' equity remains deeply underwater.

AI Insight: STRO Ratio Trends

Sutro swung to near-breakeven operating margin in Q2 2025 after severe losses, but profitability remains elusive and data gaps obscure recent trajectory.

• Operating margin improved dramatically from -189.4% in Q2 2024 to -5.2% in Q2 2025, signaling meaningful progress toward cash flow positivity.

• Net profit margin narrowed from -186.8% in Q2 2024 to -18.0% in Q2 2025, reflecting better cost control despite ongoing losses.

• ROA remains deeply negative at -63.6% TTM and -17.5% in Q2 2025, indicating the company continues destroying shareholder capital.

⚠ Data gaps in Q3 2025 and Q4 2025 prevent assessment of whether Q2 2025's margin recovery sustained or reversed.

⚠ TTM operating margin of -120.0% vs. Q2 2025 of -5.2% suggests significant seasonal or one-time items masking underlying burn.

Get alerted when STRO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SUTRO BIOPHARMA, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STRO

BVF INC/IL
$31.2M1,251,788 sh
Affinity Asset Advisors, LLC
$26.6M1,069,519 sh
Samsara BioCapital, LLC
$26.5M1,062,872 sh
Kynam Capital Management, LP
$21.7M872,558 sh
ORBIMED ADVISORS LLC
$20.0M801,144 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.9M720,442 sh
EVENTIDE ASSET MANAGEMENT, LLC
$17.8M715,307 sh
PERCEPTIVE ADVISORS LLC
$17.8M715,307 sh
RA CAPITAL MANAGEMENT, L.P.
$17.8M715,307 sh
Point72 Asset Management, L.P.
$17.2M692,111 sh

Fund	Value	Shares
BVF INC/IL	$31.2M	1,251,788
Affinity Asset Advisors, LLC	$26.6M	1,069,519
Samsara BioCapital, LLC	$26.5M	1,062,872
Kynam Capital Management, LP	$21.7M	872,558
ORBIMED ADVISORS LLC	$20.0M	801,144
VANGUARD CAPITAL MANAGEMENT LLC	$17.9M	720,442
EVENTIDE ASSET MANAGEMENT, LLC	$17.8M	715,307
PERCEPTIVE ADVISORS LLC	$17.8M	715,307
RA CAPITAL MANAGEMENT, L.P.	$17.8M	715,307
Point72 Asset Management, L.P.	$17.2M	692,111

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STRO on your watchlist

Track score changes the day SUTRO BIOPHARMA, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STRO a good stock to buy?

13F Pro's AI-powered analysis of SUTRO BIOPHARMA, INC. (STRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STRO are available on the STRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STRO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SUTRO BIOPHARMA, INC.'s investment landscape.